

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Diabetes*

**Manuscript NO:** 80080

**Title:** Protective effect of liraglutide on the myocardium of type 2 diabetic rats by inhibiting polyadenosine diphosphate-ribose polymerase-1

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05857226

**Position:** Peer Reviewer

**Academic degree:** PharmD

**Professional title:** Chief Pharmacist, Lecturer

**Reviewer's Country/Territory:** Croatia

**Author's Country/Territory:** China

**Manuscript submission date:** 2022-09-16

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-09-16 07:00

**Reviewer performed review:** 2022-09-16 12:12

**Review time:** 5 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

**Peer-reviewer  
statements**

Peer-Review: [☒] Anonymous [☐] Onymous

Conflicts-of-Interest: [☐] Yes [☒] No

## SPECIFIC COMMENTS TO AUTHORS

Dear authors, Thank you very much for the opportunity to read and comment on your manuscript. I have no comments regarding the composition of the manuscript. However, I have some comments that would increase the quality of your work. □

You are missing Introduction section title. It should be on the new page. I recommend adjusting the manuscript style according to the Baishideng Publishing Group Inc. requirements (e.g., key words, brackets, titles, subtitles, references, etc.). You can check previous review articles published in the World Journal of Diabetes. □ Please adjust abbreviations (uppercase and lowercase) once mentioned in the manuscript. e.g. Parp-1 into PARP-1. Also please explain abbreviations when you use them first time in the text (e.g., SPF male SD rats, LSD, TC, TG, LDL-C etc). □ Lalu peptid stands for what? Can you explain? □ Please explain abbreviations used in the Tables and Figures. I recommend adjusting the manuscript style according to the Baishideng Publishing Group Inc. requirements (e.g., key words, brackets, titles, subtitles, references, etc.). You can check previous review articles published in the World Journal of Diabetes. □ Can you rephrase sentence to be more understandable “Compared with the that in normal...” □ I suggest to define endpoints (primary, secondary, etc.) of experiment in the Methods section. It is not clear what are endpoints of a trial. □ I suggest to retype Chinese into English description of figures (e.g., pathology results etc.) □ I suggest to retype “Many studies at home and abroad have shown....” into Many studies have shown... □ I suggest to cite trials that you mention (e.g., LEADER, SUSTAIN-6)

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Diabetes*

**Manuscript NO:** 80080

**Title:** Protective effect of liraglutide on the myocardium of type 2 diabetic rats by inhibiting polyadenosine diphosphate-ribose polymerase-1

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05126185

**Position:** Editorial Board

**Academic degree:** PhD

**Professional title:** Associate Professor

**Reviewer's Country/Territory:** South Korea

**Author's Country/Territory:** China

**Manuscript submission date:** 2022-09-16

**Reviewer chosen by:** Dong-Mei Wang

**Reviewer accepted review:** 2022-10-28 12:53

**Reviewer performed review:** 2022-11-03 06:15

**Review time:** 5 Days and 17 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

**Peer-reviewer  
statements**

Peer-Review: [☒] Anonymous [☐] Onymous

Conflicts-of-Interest: [☐] Yes [☒] No

#### **SPECIFIC COMMENTS TO AUTHORS**

I am really grateful to review this manuscript. In my opinion, this manuscript can be published once some revision is done successfully. This study used animal experiment and univariate analysis to examine the effects of liraglutide intervention on type-2 diabetic rats. I would argue that this is a great achievement. However, an increasing amount of literature employs deep learning to investigate the effects of intervention in animal experiment. I would like to suggest the authors to address this issue in Discussion.

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** *World Journal of Diabetes*

**Manuscript NO:** 80080

**Title:** Protective effect of liraglutide on the myocardium of type 2 diabetic rats by inhibiting polyadenosine diphosphate-ribose polymerase-1

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05857226

**Position:** Peer Reviewer

**Academic degree:** PharmD

**Professional title:** Chief Pharmacist, Lecturer

**Reviewer's Country/Territory:** Croatia

**Author's Country/Territory:** China

**Manuscript submission date:** 2022-09-16

**Reviewer chosen by:** Han Zhang

**Reviewer accepted review:** 2022-12-01 13:56

**Reviewer performed review:** 2022-12-02 12:15

**Review time:** 22 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

statements

Conflicts-of-Interest: [ ☐ ] Yes [ ☒ ] No

## **SPECIFIC COMMENTS TO AUTHORS**

I have no further comments.